ABSTRACT Background. Although recommendations for breast cancer follow-up frequency exist, current follow-up guidelines are standardized, without consideration of individual patient characteristics. Some studies suggest oncologists are using these characteristics to tailor follow-up recommendations, but it is unclear how this is translating into practice. The objective of this study was to examine current patterns of oncologist breast cancer follow-up and determine the association between patient and tumor characteristics and follow-up frequency. Methods. The Surveillance, Epidemiology, and End Results (SEER)-Medicare database was used to identify stage I-III breast cancer patients diagnosed 2000-2007 (n = 39,241). Oncologist follow-up visits were defined using Medicare specialty provider codes and the linked AMA Masterfile. Multinomial logistic regression determined the association between patient and tumor characteristics and oncologist follow-up visit frequency. Results. Younger age (p \ 0.001), positive nodes (p \ 0.001), estrogen receptor/progesterone receptor positivity (p \ 0.001), and increasing treatment intensity (p \ 0.001) were most strongly associated with more frequent follow-up. However, after accounting for these characteristics, significant variation in follow-up frequency was observed. In addition to patient factors, the number and types of oncologists involved in follow-up were associated with follow-up frequency (p \ 0.001). Types of oncologists providing follow-up varied, with medical oncologists the sole providers of follow-up for 19-51 % of breast cancer survivors. Overall, 58 % of patients received surgical oncology, and 51 % undergoing radiation received radiation oncology follow-up, usually in combination with medical oncology. Conclusions. Significant variation in breast cancer followup frequency exists. Developing follow-up guidelines tailored for patient, tumor, and treatment characteristics while also providing guidance on who should provide follow-up has the potential to increase clinical efficiency.
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Follow-up every 3-6 months is recommended for the 3 million current U.S. breast cancer survivors. [1] [2] [3] Goals of follow-up include early detection of new cancers, locoregional recurrence, distant metastases, and treatment toxicity. Both the American Society of Clinical Oncology and the National Comprehensive Cancer Network provide recommendations for follow-up frequency. 2, 3 However, these follow-up guidelines are standardized, without consideration of individual patient characteristics. This is significant given that both patient and tumor characteristics can dramatically affect the risk and timing of recurrence. [4] [5] [6] [7] [8] Some studies suggest oncologists are using these characteristics (such as tumor size, nodal status, and molecular tumor subtype) to tailor follow-up recommendations, but it is unclear how this is translating into practice. [9] [10] [11] Understanding patient factors driving current patterns of followup is a first step toward the development of more efficient, tailored breast cancer follow-up.
Our objective was to examine current patterns of oncologist breast cancer follow-up and determine the association between patient and tumor characteristics and follow-up frequency. We hypothesized that significant drivers of the frequency of follow-up patients receive would include nodal status (increased frequency if node positive) and estrogen receptor (ER) and progesterone receptor (PR) status (decreased frequency if positive).
METHODS
This study was reviewed by the University of Wisconsin institutional review board and granted a waiver of consent.
Data Source
The linked Surveillance, Epidemiology, and End Results (SEER)-Medicare database was used to identify patients diagnosed with breast cancer from 2000 to 2007. The SEER-Medicare data resource has been previously described by our group and others and is an established resource for studying longitudinal cancer in elderly patients.
12-16

Patient Selection
All female Medicare-enrolled patients aged 66 years and older diagnosed with stage I-III invasive breast cancer within any SEER region between 2000 and 2007 were eligible (Fig. 1 9020) codes were used to identify breast cancer patients. Patients were included in the study if they underwent definitive breast surgery (Appendix). Continuous enrollment in Medicare part A and B was required for 1 year before diagnosis to allow ascertainment of comorbidities through a minimum of 2 years after diagnosis, death, or December 31, 2009 (whichever came first), to assess the follow-up received. Patients were excluded if they were enrolled in a health maintenance organization during the same time period.
Patients were also excluded if they were diagnosed with another malignancy 5 years before or after the date of breast cancer diagnosis.
Primary Outcome Variable
The primary outcome was frequency of oncologist follow-up visits. Any visit with a surgical, medical, or radiation oncologist was considered to be an oncologist visit; in this context, general surgeons who provided breast cancer care were considered to be surgical oncologists. To ensure only follow-up (rather than active treatment) visits were captured, the evaluable follow-up window began 12 months after diagnosis or a minimum of 3 months after last treatment (excluding endocrine therapy and reconstructive surgery). 17 A minimum of 1 year of follow-up was required. [18] [19] [20] Our follow-up window ended 3 months before these events to minimize bias associated with inappropriately capturing clinic visits for assessment of recurrence or ongoing treatment (which would overestimate the number of follow-up visits occurring).
All G0101, G0245-G0250, G0344, G0375, G0376) were assessed. We defined oncologist visits using the Medicare specialty provider code and linked AMA Masterfile. 21, 22 In cases where both the AMA Masterfile and Medicare specialty provider code were missing or did not indicate an oncology specialty, we evaluated physicians' claims to determine whether their clinical practice was consistent with being an oncologist. 21 A breast cancer ICD-9 diagnosis code was required for any oncologist visits identified by these claims-based definitions. 21 
Patient-Related Variables
Basic demographics, including date of birth, gender, race/ ethnicity, and marital status, were obtained from SEER data. Socioeconomic status was assessed using census tract median level of household income and median level of education. Residence location was assessed using the Rural Urban Commuting Area codes. The Deyo implementation of the Charlson comorbidity index was used to assess patient comorbidities. 23, 24 The 6th edition of the American Joint Committee on Cancer (AJCC) staging scheme was used to assign stage on the basis of SEER tumor size and number of disease-positive nodes. 25 ER/PR status and tumor grade were also assessed using SEER. Definitions for treatment received are included in the Appendix. Endocrine therapy was not able to be assessed because oral medications are not included in Medicare part A and B. Therefore, ER/PR status was used as a surrogate for receipt of endocrine therapy.
Analysis
Summary statistics were used to describe patient demographic and disease characteristics for the entire cohort. Each patient was categorized as having \2, 2-4, and [4 visits per year to approximate the 25th, 25th to 75th, and 75th percentiles in our data. Multinomial logistic regression identified patient characteristics associated with receipt of more frequent follow-up (compared to a baseline of \2 visits per year), adjusting for sociodemographics, tumor characteristics, and treatment, and using robust estimates of the variance to account for clustering. Primary tumor size and number of positive lymph nodes were included in the model rather than AJCC stage to allow assessment of how each component influenced follow-up frequency. A series of bar graphs representing the frequency of follow-up were created to better explore the relationship between treatment received and follow-up frequency. Additional bar graphs were generated representing the type of oncologists involved in follow-up care.
RESULTS
Demographic and tumor characteristics for the 39,421 patients meeting inclusion criteria for the study are presented in Table 1 . The majority of patients had AJCC stage I disease (59 %), with 36 % stage II disease and 5 % stage III disease. Patients had a median 2.67 follow-up visits per year. Younger age, positive nodes, ER/PR positivity, and increasing intensity of treatment were most strongly associated with receipt of more frequent follow-up on multivariate modeling (Table 2) Given the strong relationship between treatment received and follow-up frequency, treatment received was examined in more detail (Fig. 2) . As was demonstrated in our multivariable risk-adjusted model, a trend toward increased visit frequency with increased intensity of treatment was observed. For example, [43 % of patients who underwent lumpectomy and were treated with both chemotherapy and radiation received [4 follow-up visits per year versus 24 % of patients undergoing lumpectomy and radiation alone. However, significant variation in frequency of follow-up received was observed. This is most clearly appreciated in the lumpectomy, radiation, and no-chemotherapy cohort (Fig. 2) . Forth-eight percent of these patients received 2-4 follow-up visits per year. However, the remaining patients were as likely to receive \2 visits per year as they were [4 visits per year. This variation persisted after controlling for other patient sociodemographic and tumor characteristics (i.e., ER/PR receptor and nodal status).
Increasing treatment modalities employed means that multiple oncologists are involved in patients' active treatment and have the potential to be involved in follow-up care. As expected, an increasing number of oncologists involved in follow-up was associated with increased followup frequency (p \ 0.001 on univariate analysis). 
DISCUSSION
We identified significant variation in frequency of oncologist follow-up visits: variation was influenced by patient demographics (i.e., age), tumor characteristics (nodal status, ER/PR status), and treatment received. This suggests that oncologists may be using these patient factors to tailor follow-up recommendations for a given patient. We had hypothesized that ER/PR and nodal status would have the strongest association with follow-up frequency. Both of these factors were associated with frequency of follow-up visits, although ER/PR positivity was associated with more rather than less frequent follow-up, the opposite of what we had hypothesized a priori. However, although both of these factors were associated with frequency of follow-up visits, the type of treatment a patient received appeared to have a stronger overall influence. An obvious possible explanation for the association between treatment received and frequency of follow-up visits is that patients with higher-risk tumors are also those most likely to receive multiple treatment modalities, making treatment a surrogate for tumor characteristics. However, because both tumor characteristics and treatment received were associated with follow-up frequency on multivariable modeling, this suggests that the association with treatment received cannot be explained by tumor characteristics alone. Another explanation is that risk of treatment toxicity is being considered in follow-up recommendations. This argument is indirectly supported by the observation that ER/PR positivity (a surrogate for endocrine therapy) was associated with more frequent follow-up than ER/PR negative; this increased follow-up frequency could be explained by ongoing monitoring for treatment toxicity. Finally, the type and number of oncologists involved in a patient's follow-up care may influence follow-up frequency. Current guidelines do not provide guidance on what type of oncologists should provide follow-up or what the responsibilities of each should be. Consequently, challenges associated with coordinating multidisciplinary care may lead to more frequent follow-up for patients who receive care from multiple oncologists. Given the inconsistency we observed in the number and type of oncologists providing follow-up care for breast cancer survivors, the person who provides follow-up may be a critical factor driving the frequency of follow-up breast cancer survivors receive. This suggests that coordinating care among different oncology specialties may hold the greatest potential for increasing efficiency. 
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Reference Limitations to our study exist. First, we are unable to directly assess use of oral medications (specifically endocrine therapy) in the SEER-Medicare database. To address this, we utilized ER/PR positivity as a surrogate for receipt of oral endocrine therapy in our analyses. This assumption is somewhat limited by issues related to compliance with recommended endocrine therapy. 26 Additionally, as our study was limited to Medicare patients, findings cannot be generalized to younger women; however, given that over 50 % of breast cancer patients are [65 years of age, our results are applicable to the majority of women. 27 Finally, we are unable to assess intent of the follow-up visits-that is, was a visit truly for surveillance, versus evaluation of a symptom? By categorizing our frequency of follow-up into three categories, we were able to adjust for some of this uncertainty.
In summary, we determined that significant variation exists in the frequency of oncologist follow-up visits received by older breast cancer survivors. Some variation may be appropriate and attributed to tailoring of follow-up on the basis of patient demographics, tumor characteristics, and/or treatment received. As we begin to think about increasing the efficiency of breast cancer follow-up, treatment received is an appealing factor to guide tailored follow-up because it indirectly accounts for tumor characteristics as well as directly accounting for treatment toxicity and could easily be incorporated into current clinical practice guideline algorithms.
We also determined that the type of oncologists providing follow-up is another potentially important cause for the observed variation. Given the lack of guidance on who should provide follow-up and the challenges associated with care coordination, identification of who should provide follow-up with delineation of specific responsibilities during follow-up has the potential to increase clinical efficiency, decrease cost, and ease some of the burden on the oncology workforce. 
APPENDIX
See Table 3 . 
